70 related articles for article (PubMed ID: 19287064)
1. Expression of class III beta-tubulin in colorectal carcinomas: an immunohistochemical study using TU-20 & TuJ-1 antibody.
Jirásek T; Cipro S; Musilová A; Kubecová M; Mandys V
Indian J Med Res; 2009 Jan; 129(1):89-94. PubMed ID: 19287064
[TBL] [Abstract][Full Text] [Related]
2. Expression of class III beta-tubulin in malignant epithelial tumours: an immunohistochemical study using TU-20 and TuJ-1 antibodies.
Jirásek T; Písaríková E; Viklický V; Mandys V
Folia Histochem Cytobiol; 2007; 45(1):41-5. PubMed ID: 17378245
[TBL] [Abstract][Full Text] [Related]
3. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
4. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
5. Expression of unphosphorylated class III beta-tubulin isotype in neuroepithelial cells demonstrates neuroblast commitment and differentiation.
Fanarraga ML; Avila J; Zabala JC
Eur J Neurosci; 1999 Feb; 11(2):517-27. PubMed ID: 10073918
[TBL] [Abstract][Full Text] [Related]
6. [Merkel cell carcinoma--immunohistochemical study in a group of 11 patients].
Jirásek T; Matej R; Pock L; Knotková I; Mandys V
Cesk Patol; 2009 Jan; 45(1):9-13. PubMed ID: 19402315
[TBL] [Abstract][Full Text] [Related]
7. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.
Urano N; Fujiwara Y; Doki Y; Kim SJ; Miyoshi Y; Noguchi S; Miyata H; Takiguchi S; Yasuda T; Yano M; Monden M
Int J Oncol; 2006 Feb; 28(2):375-81. PubMed ID: 16391792
[TBL] [Abstract][Full Text] [Related]
9. Expression of unphosphorylated class III beta-tubulin isotype in neuroepithelial cells demonstrates neuroblast commitment and differentiation.
Fanarraga ML; Avila J; Zabala JC
Eur J Neurosci; 1999 Feb; 11(2):516-527. PubMed ID: 10051752
[TBL] [Abstract][Full Text] [Related]
10. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
[TBL] [Abstract][Full Text] [Related]
11. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
[TBL] [Abstract][Full Text] [Related]
12. Expression of class III beta-tubulin in neuroendocrine tumours of gastrointestinal tract.
Jirásek T; Mandys V; Viklický V
Folia Histochem Cytobiol; 2002; 40(3):305-10. PubMed ID: 12219841
[TBL] [Abstract][Full Text] [Related]
13. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
14. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
[TBL] [Abstract][Full Text] [Related]
15. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
16. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
[TBL] [Abstract][Full Text] [Related]
17. Expression of class III beta-tubulin in normal and neoplastic human tissues.
Dráberová E; Lukás Z; Ivanyi D; Viklický V; Dráber P
Histochem Cell Biol; 1998 Mar; 109(3):231-9. PubMed ID: 9541471
[TBL] [Abstract][Full Text] [Related]
18. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
[TBL] [Abstract][Full Text] [Related]
19. Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site.
Sève P; Reiman T; Isaac S; Trillet-Lenoir V; Lafanéchère L; Sawyer M; Dumontet C
Anticancer Res; 2008; 28(2B):1161-7. PubMed ID: 18505052
[TBL] [Abstract][Full Text] [Related]
20. Neuron-associated class III beta-tubulin isotype, microtubule-associated protein 2, and synaptophysin in human retinoblastomas in situ. Further immunohistochemical observations on the Flexner-Wintersteiner rosettes.
Katsetos CD; Herman MM; Frankfurter A; Uffer S; Perentes E; Rubinstein LJ
Lab Invest; 1991 Jan; 64(1):45-54. PubMed ID: 1703586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
